Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α

: Liver cancer stem cells (LCSCs) are responsible for the initiation, progression and chemoresistance of liver cancer. However, no agent targeting LCSC is available in the clinic to date. Here, we investigated the effects of targeting protein arginine methyltransferase 5 (PRMT5), an epigenetic regul...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Theranostics 2019-01, Vol.9 (9), p.2606-2617
Hauptverfasser:	Zheng, Bai-Nan, Ding, Chen-Hong, Chen, Shi-Jie, Zhu, Kongkai, Shao, Jingwei, Feng, Jifeng, Xu, Wen-Ping, Cai, Ling-Yan, Zhu, Chang-Peng, Duan, Wenhu, Ding, Jin, Zhang, Xin, Luo, Cheng, Xie, Wei-Fen
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacology Carcinoma, Hepatocellular - drug therapy Cell Differentiation - drug effects Cell Proliferation - drug effects Disease Models, Animal Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - pharmacology Hepatocyte Nuclear Factor 4 - biosynthesis Heterografts Humans Liver Neoplasms - drug therapy Mice, Inbred BALB C Mice, Nude Neoplasm Transplantation Neoplastic Stem Cells - drug effects Protein-Arginine N-Methyltransferases - antagonists & inhibitors Research Paper Transcription, Genetic Treatment Outcome Tumor Cells, Cultured
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!